A new study suggests that GLP-1 receptor agonists—including Ozempic, Wegovy, and Mounjaro—may improve survival in patients with colon cancer. These drugs, commonly used for type 2 diabetes and weight loss, were linked to a five-year mortality rate of 15.5%, compared with 37.1% in patients not taking them, meaning users were less than half as likely […]
The FDA has approved vorasidenib, the first targeted drug for people with Grade 2 diffuse glioma that carries an IDH1 or IDH2 mutation. This marks an important advance for a slow-growing but incurable brain cancer. About 3,500 Americans are diagnosed with this type of tumor each year. Most cases (70–80%) have an IDH1 mutation. Patients
FDA Approves First Targeted Therapy for IDH-Mutant Low-Grade Glioma Read More »
DB-1305/BNT325 is an investigational antibody-drug conjugate (ADC) designed to target TROP-2, a protein commonly found on triple-negative breast cancer (TNBC) cells. Once attached, it delivers a topoisomerase-1 inhibitor to help kill the cancer. Each antibody carries about four drug molecules. This treatment is being tested in a Phase 1/2 study in patients with metastatic TNBC
DB-1305/BNT325 Promising for Heavily Pretreated Triple-Negative Breast Cancer Read More »
The Phase 3 PEAK trial showed that adding the targeted drug bezuclastinib to sunitinib significantly improved outcomes for people with advanced gastrointestinal stromal tumors (GIST) who could not take imatinib or whose cancer had progressed on it. The combination cut the risk of cancer progression or death by half compared with sunitinib alone. Patients receiving
New Drug Combo Shows Major Benefit for Imatinib-Resistant GIST Read More »
A Phase 3 trial, STELLAR-303, shows that combining zanzalintinib (XL092) with atezolizumab (Tecentriq) extends survival in patients with metastatic colorectal cancer compared with standard treatment regorafenib (Stivarga). Patients previously treated with chemotherapy and who were not MSI-high lived 10.9 months on the combination versus 9.4 months on regorafenib, with slower disease progression (3.7 vs. 2.0 months) and higher disease
Glioblastoma multiforme (GBM) is the most aggressive adult brain cancer, and treatment remains challenging. Standard therapy combines surgery, radiation, and temozolomide (TMZ) chemotherapy, sometimes with tumor-treating fields. A key factor is MGMT promoter methylation—tumors with methylation respond better to TMZ, improving survival from about 12 to nearly 15 months. Genetic profiling, including TERT promoter mutations, EGFR
Breakthrough Treatments Show Promise Against Aggressive Brain Tumor Read More »
A Researchers have uncovered how lung cancer rapidly develops resistance to osimertinib, a key drug for EGFR-mutant tumors. Resistance can emerge within six to eight weeks of starting treatment, earlier than previously thought. The study identified a protein, METTL7A, as a critical driver of this process. METTL7A remodels chromatin, making it easier for cancer cells
New Protein Target May Stop Early Drug Resistance in EGFR-Mutant Lung Cancer Read More »
A new mRNA vaccine targeting BCMA—a protein highly expressed on multiple myeloma (MM) cells—has shown promising preclinical results. Using lipid nanoparticle (LNP) delivery, the vaccine effectively triggered a strong, specific immune response against MM cells in both lab and mouse studies. Unlike current therapies such as CAR T-cells, which can be limited by T-cell exhaustion
New BCMA mRNA Vaccine Shows Strong Potential Against Multiple Myeloma Read More »
Brain cancer continues to be a major global health burden. Patients often experience persistent headaches, seizures, memory loss, and difficulty thinking, which significantly affect quality of life. Glioblastoma (GBM) is the most common and deadliest type of brain tumor. It grows rapidly, infiltrates normal brain tissue, and is very difficult to treat. Standard care includes surgery
New Research Highlights Nuclear Receptors as Promising Targets in Brain Cancer Treatment Read More »
GFH375, an experimental oral drug, is showing promising results for patients with advanced KRAS G12D–mutant pancreatic cancer, a mutation present in roughly 40% of pancreatic ductal adenocarcinomas. The early-phase trial involved daily 600 mg doses in patients who had already received multiple treatments. The therapy produced tumor shrinkage in 40.7% of patients, all partial responses, and
New KRAS G12D Drug Shows Strong Response in Advanced Pancreatic Cancer Read More »